Gagyor Ildiko, Madhok Vishnu B, Daly Fergus, Somasundara Dhruvashree, Sullivan Michael, Gammie Fiona, Sullivan Frank
Department of General Practice/Family Medicine, University of Göttingen, Humboldtalle 38, Göttingen, Lower Saxony, Germany, 37073.
Cochrane Database Syst Rev. 2015 May 4(5):CD001869. doi: 10.1002/14651858.CD001869.pub5.
Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. Significant morbidity can be associated with severe cases of Bell's palsy.
To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy.
On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, DARE, NHS EED, and HTA. We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies.
We considered randomised controlled trials or quasi-randomised controlled trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that had a high risk of bias in several domains.
Pairs of authors independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures.
Eleven trials, including 2883 participants, met the inclusion criteria and are included in the final analysis. We added four studies to the previous review for this update. Some of the trials were small, and a number were at high or unclear risk of bias. Other trials did not meet current best standards in allocation concealment and blinding. Incomplete recoveryWe found no significant benefit from adding antivirals to corticosteroids in comparison with corticosteroids alone for people with Bell's palsy (risk ratio (RR) 0.69, 95% confidence interval (CI) 0.47 to 1.02, n = 1715). For people with severe Bell's palsy (House-Brackmann scores of 5 and 6 or the equivalent in other scales), we found a reduction in the rate of incomplete recovery at month six when antivirals plus corticosteroids were used (RR 0.64, 95% CI 0.41 to 0.99, n = 478). The outcome for the participants receiving corticosteroids alone was significantly better than for those receiving antivirals alone (RR 2.09, 95% CI 1.36 to 3.20, n = 1169). The treatment effect of placebo was significantly lower than that of antivirals plus corticosteroids (RR 0.56, 95% CI 0.41 to 0.76, n = 658). Antivirals alone had a non-significant detrimental effect on the outcome compared with placebo (RR 1.10, 95% CI 0.87 to 1.40, n = 658). Motor synkinesis or crocodile tearsIn three trials comparing antivirals and corticosteroids with corticosteroids and placebo that assessed this outcome, we found a significant difference in long-term sequelae in favour or antivirals plus corticosteroids (RR 0.73, 95% CI 0.54 to 0.99, n = 869). Three trials comparing antivirals alone with corticosteroids alone investigating this outcome showed fewer sequelae with corticosteroids (RR 1.44, 95% CI 1.11 to 1.85, n = 873). We found no data on long-term sequelae for other comparisons. Adverse events Adverse event data were available in three studies giving comparison data on 1528 participants. None of the four comparisons (antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment; antivirals versus corticosteroids; antivirals plus corticosteroids versus placebo; antivirals versus placebo) showed significant differences in adverse events between treatment and control arms. We could find no correlation with specific treatment within these results.
AUTHORS' CONCLUSIONS: Moderate-quality evidence from randomised controlled trials showed no additional benefit from the combination of antivirals with corticosteroids compared to corticosteroids alone or with placebo, and no benefit from antivirals alone compared to placebo, for the treatment of Bell's palsy. Moderate-quality evidence showed a small but just significant benefit of combination therapy compared with corticosteroids alone in severe Bell's palsy. We found no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids.
皮质类固醇广泛用于治疗特发性面神经麻痹(贝尔麻痹),但联合使用抗病毒药物的疗效尚不确定。严重的贝尔麻痹病例可能会导致显著的发病率。
评估单独使用抗病毒治疗或与其他疗法联合治疗贝尔麻痹的效果。
2014年10月7日,我们检索了Cochrane神经肌肉疾病专业组注册库、Cochrane系统评价数据库、医学期刊数据库、荷兰医学文摘数据库、拉丁美洲和加勒比地区卫生科学数据库、循证医学数据库、英国国家卫生服务部经济评价数据库及卫生技术评估数据库。我们还查阅了已识别试验的参考文献,并联系了试验作者、该领域的知名专家及相关制药公司,以识别其他已发表或未发表的数据。我们检索了临床试验注册库以查找正在进行的研究。
我们纳入了关于抗病毒药物联合或不联合皮质类固醇与对照疗法治疗贝尔麻痹的随机对照试验或半随机对照试验。我们排除了在多个领域存在高偏倚风险的试验。
两位作者使用Cochrane标准程序,独立评估试验的相关性、纳入标准及偏倚风险。
11项试验,共2883名参与者,符合纳入标准并纳入最终分析。本次更新在前次综述基础上新增了4项研究。部分试验规模较小,一些试验存在高偏倚风险或偏倚风险不明。其他试验在分配隐藏和盲法方面未达到当前最佳标准。
对于贝尔麻痹患者,与单独使用皮质类固醇相比,联合使用抗病毒药物未显示出显著益处(风险比(RR)0.69,95%置信区间(CI)0.47至1.02,n = 1715)。对于重度贝尔麻痹患者(House - Brackmann评分为5和6或其他量表的等效评分),我们发现使用抗病毒药物加皮质类固醇时,在第6个月不完全恢复率有所降低(RR 0.64,95% CI 0.41至0.99,n = 478)。单独接受皮质类固醇治疗的参与者的结果明显优于单独接受抗病毒药物治疗的参与者(RR 2.09,95% CI 1.36至3.20,n = 1169)。安慰剂的治疗效果显著低于抗病毒药物加皮质类固醇(RR 0.56,95% CI 0.41至0.76,n = 658)。与安慰剂相比,单独使用抗病毒药物对结果有非显著的不利影响(RR 1.10,95% CI 0.87至1.40,n = 658)。
在三项比较抗病毒药物和皮质类固醇与皮质类固醇和安慰剂并评估此结果的试验中,我们发现长期后遗症存在显著差异,支持抗病毒药物加皮质类固醇(RR 0.73,95% CI 0.54至0.99,n = 869)。三项比较单独使用抗病毒药物与单独使用皮质类固醇并研究此结果的试验显示,皮质类固醇的后遗症较少(RR 1.44,95% CI 1.11至1.85,n = 873)。我们未找到其他比较的长期后遗症数据。
三项研究提供了1528名参与者的不良事件比较数据。四项比较(抗病毒药物加皮质类固醇与皮质类固醇加安慰剂或不治疗;抗病毒药物与皮质类固醇;抗病毒药物加皮质类固醇与安慰剂;抗病毒药物与安慰剂)中,治疗组和对照组之间在不良事件方面均未显示出显著差异。在这些结果中,我们未发现与特定治疗的相关性。
随机对照试验的中等质量证据表明,与单独使用皮质类固醇或安慰剂相比,抗病毒药物与皮质类固醇联合使用未显示出额外益处,与安慰剂相比,单独使用抗病毒药物也无益处,用于治疗贝尔麻痹。中等质量证据表明,在重度贝尔麻痹中,联合治疗与单独使用皮质类固醇相比有小但显著的益处。我们发现与安慰剂或皮质类固醇相比,使用抗病毒药物未显著增加不良事件发生率。